We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol-Myers (BMY) Announces Results From Opdivo Combo Study
Read MoreHide Full Article
Bristol-Myers (BMY - Free Report) announced positive primary results from the phase II/III RELATIVITY-047 (CA224-047) study. The study is evaluating a fixed-dose combination of relatlimab, an anti-LAG-3 antibody, and immuno-oncology drug, Opdivo (nivolumab), compared to Opdivo alone in patients with previously untreated metastatic or unresectable melanoma.
The primary endpoint of the trial is progression-free survival (PFS) by Blinded Independent Central Review (BICR) and the secondary endpoints are overall survival (OS) and objective response rate (ORR).
A total of 714 patients were randomized 1:1 to receive a fixed-dose combination of relatlimab 160 mg and Opdivo 480 mg or Opdivo 480 mg by intravenous infusion every four weeks until disease recurrence, unacceptable toxicity or withdrawal of consent.
The study met its primary endpoint of PFS. Follow-up for the secondary endpoints of OS and ORR is ongoing.
The fixed-dose combination was well-tolerated and there were no new safety signals reported in either the relatlimab and Opdivo combination arm or the Opdivo arm.
Relatlimab is a LAG-3-blocking antibody that binds to LAG-3 on T cells, restoring effector function of exhausted T cells. The company is evaluating relatlimab, its LAG-3-blocking antibody, in clinical trials, in combination with other agents in a variety of tumor types.
The encouraging primary results of this study suggest that targeting the LAG-3 pathway in combination with PD-1 inhibition may enhance the immune response and help improve outcomes for these patients.
Approval of new drugs will add a new stream of revenues for Bristol Myers, which should propel growth in the coming quarters.
The company’s shares have gained 2.2% in the year so far against the industry's decline of 2.7%.
Opdivo, a key drug in the company’s portfolio, returned to growth in the fourth quarter after declining in the third quarter amid stiff competition from Merck’s (MRK - Free Report) Keytruda and Roche’s (RHHBY - Free Report) Tecentriq in key indications.
Moderna’s earnings estimates for 2021 have increased to $22.72 from $14.74 in the past 30 days.
These Stocks Are Poised to Soar Past the Pandemic
The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.
Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.
Image: Bigstock
Bristol-Myers (BMY) Announces Results From Opdivo Combo Study
Bristol-Myers (BMY - Free Report) announced positive primary results from the phase II/III RELATIVITY-047 (CA224-047) study. The study is evaluating a fixed-dose combination of relatlimab, an anti-LAG-3 antibody, and immuno-oncology drug, Opdivo (nivolumab), compared to Opdivo alone in patients with previously untreated metastatic or unresectable melanoma.
The primary endpoint of the trial is progression-free survival (PFS) by Blinded Independent Central Review (BICR) and the secondary endpoints are overall survival (OS) and objective response rate (ORR).
A total of 714 patients were randomized 1:1 to receive a fixed-dose combination of relatlimab 160 mg and Opdivo 480 mg or Opdivo 480 mg by intravenous infusion every four weeks until disease recurrence, unacceptable toxicity or withdrawal of consent.
The study met its primary endpoint of PFS. Follow-up for the secondary endpoints of OS and ORR is ongoing.
The fixed-dose combination was well-tolerated and there were no new safety signals reported in either the relatlimab and Opdivo combination arm or the Opdivo arm.
Relatlimab is a LAG-3-blocking antibody that binds to LAG-3 on T cells, restoring effector function of exhausted T cells. The company is evaluating relatlimab, its LAG-3-blocking antibody, in clinical trials, in combination with other agents in a variety of tumor types.
The encouraging primary results of this study suggest that targeting the LAG-3 pathway in combination with PD-1 inhibition may enhance the immune response and help improve outcomes for these patients.
Approval of new drugs will add a new stream of revenues for Bristol Myers, which should propel growth in the coming quarters.
The company’s shares have gained 2.2% in the year so far against the industry's decline of 2.7%.
Opdivo, a key drug in the company’s portfolio, returned to growth in the fourth quarter after declining in the third quarter amid stiff competition from Merck’s (MRK - Free Report) Keytruda and Roche’s (RHHBY - Free Report) Tecentriq in key indications.
Bristol-Myers currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the biotech sector is Moderna (MRNA - Free Report) , which carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Moderna’s earnings estimates for 2021 have increased to $22.72 from $14.74 in the past 30 days.
These Stocks Are Poised to Soar Past the Pandemic
The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.
Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.
See the 5 high-tech stocks now>>